Currently, C1INH prepared from human plasma (CinryzeTM) has been approved for the treatment of hereditary angioedema, a rare autosomal dominant disease manifested by recurrent acute attacks of edema that results from C1INH deficiency (70). The gene discussed is SERPING1; the disease is hereditary angioedema.